HSBC Holdings’s Kyntra Bio KYNB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-1,199
| Closed | -$9.51K | – | 3087 |
|
|
2025
Q1 | $9.51K | Sell |
1,199
-889
| -43% | -$10.7K | ﹤0.01% | 2988 |
|
|
2024
Q4 | $26.8K | Hold |
2,088
| – | – | ﹤0.01% | 3041 |
|
|
2024
Q3 | $21.4K | Sell |
2,088
-418
| -17% | -$6.31K | ﹤0.01% | 2945 |
|
|
2024
Q2 | $58.4K | Sell |
2,506
-802
| -24% | -$24.8K | ﹤0.01% | 2804 |
|
|
2024
Q1 | $194K | Buy |
3,308
+49
| +2% | +$2.11K | ﹤0.01% | 2699 |
|
|
2023
Q4 | $69.8K | Buy |
3,259
+1,088
| +50% | +$16.4K | ﹤0.01% | 2629 |
|
|
2023
Q3 | $47.1K | Sell |
2,171
-958
| -31% | -$37.6K | ﹤0.01% | 2636 |
|
|
2023
Q2 | $211K | Buy |
+3,129
| New | +$1.29M | ﹤0.01% | 2300 |
|
|
2022
Q4 | – | Sell |
-552
| Closed | -$182K | – | 3078 |
|
|
2022
Q3 | $182K | Buy |
552
+47
| +9% | +$15.1K | ﹤0.01% | 2653 |
|
|
2022
Q2 | $134K | Buy |
505
+40
| +9% | +$10.2K | ﹤0.01% | 2981 |
|
|
2022
Q1 | $142K | Buy |
+465
| New | +$162K | ﹤0.01% | 3065 |
|
|
2021
Q3 | – | Sell |
-570
| Closed | -$382K | – | 3037 |
|
|
2021
Q2 | $382K | Buy |
570
+201
| +54% | +$116K | ﹤0.01% | 2367 |
|
|
2021
Q1 | $314K | Sell |
369
-319
| -46% | -$340K | ﹤0.01% | 2260 |
|
|
2020
Q4 | $640K | Buy |
688
+298
| +76% | +$313K | ﹤0.01% | 2009 |
|
|
2020
Q3 | $401K | Sell |
390
-156
| -29% | -$168K | ﹤0.01% | 2071 |
|
|
2020
Q2 | $553K | Buy |
+546
| New | +$507K | ﹤0.01% | 1778 |
|
|
2020
Q1 | – | Sell |
-623
| Closed | -$673K | – | 2808 |
|
|
2019
Q4 | $673K | Buy |
623
+114
| +22% | +$116K | ﹤0.01% | 2061 |
|
|
2019
Q3 | $470K | Buy |
509
+98
| +24% | +$108K | ﹤0.01% | 2372 |
|
|
2019
Q2 | $464K | Sell |
411
-28
| -6% | -$30.6K | ﹤0.01% | 2100 |
|
|
2019
Q1 | $597K | Buy |
439
+137
| +45% | +$186K | ﹤0.01% | 2030 |
|
|
2018
Q4 | $350K | Buy |
302
+108
| +56% | +$121K | ﹤0.01% | 2244 |
|
|
2018
Q3 | $294K | Buy |
194
+1
| +0.5% | +$1.54K | ﹤0.01% | 2248 |
|
|
2018
Q2 | $301K | Buy |
193
+52
| +37% | +$67.8K | ﹤0.01% | 2282 |
|
|
2018
Q1 | $164K | Sell |
141
-21
| -13% | -$27.7K | ﹤0.01% | 2425 |
|
|
2017
Q4 | $191K | Buy |
162
+23
| +17% | +$28.8K | ﹤0.01% | 1936 |
|
|
2017
Q3 | $187K | Buy |
+139
| New | +$146K | ﹤0.01% | 2179 |
|
|
2017
Q1 | – | Sell |
-441
| Closed | -$236K | – | 2267 |
|
|
2016
Q4 | $236K | Buy |
+441
| New | +$220K | ﹤0.01% | 2423 |
|
Other funds holding KYNB
AC
CCM
HSBC Holdings's KYNB Position: Q2 2025 in Review
HSBC Holdings sold out of Kyntra Bio (KYNB) in Q2 2025, closing a stake of 1,199 shares — an estimated $9.51K sold.
HSBC Holdings first reported a position in KYNB in Q4 2016 and held it in 27 quarters. The position peaked at $673K in Q4 2019. 30 funds tracked by Wall St. Rank hold KYNB as of Q2 2025.
- HSBC Holdings reported no remaining Kyntra Bio position as of Q2 2025 after selling out during the quarter.
- HSBC Holdings sold 1,199 Kyntra Bio shares in Q2 2025, an estimated $9.51K.
- HSBC Holdings first reported a position in Kyntra Bio in Q4 2016 and held it in 27 quarters.
- HSBC Holdings's Kyntra Bio position peaked at $673K in Q4 2019.
- 30 funds tracked by Wall St. Rank held Kyntra Bio as of Q2 2025.
Based on HSBC Holdings's 13F filing for Q2 2025, filed 13 Aug 2025.